Last reviewed · How we verify

NCT06180876: RED

Effect of Remimazolam on Postoperative Delirium

Completed NA Last updated 23 February 2026
What this trial tests

NA trial testing remimazolam in General Anesthetic Drug Adverse Reaction in 264 participants. Completed in 30 January 2024.

Timeline
25 July 2022
Primary endpoint
25 January 2024
30 January 2024

Quick facts

Lead sponsorZhihong LU
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Enrollment264
Start date25 July 2022
Primary completion25 January 2024
Estimated completion30 January 2024
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Zhihong LU — full company profile →

Who can join

60 and older, any sex, with General Anesthetic Drug Adverse Reaction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Remimazolam is a novel benzodiazepine with ultra-short onset and offset of its effect. It can be used for general anesthesia. However, classical benzodiazepine such as midazolam was reported to increase the risk of postoperative delirium. Thus, the investigators aim to investigate the effect of remimazolam general anesthesia on postoperative delirium in elderly patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of remimazolam

Trials testing the same drug.

Other recruiting trials for General Anesthetic Drug Adverse Reaction

Currently open trials in the same condition.

Other Zhihong LU trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06180876.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing